Innova Captab Results: Latest Quarterly Results & Analysis

Pharmaceuticals company Innova Captab announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

• Revenue from Operations was Rs 318.2 crore in the quarter vs Rs 282.9 crore last year, registering growth of 12.5%.
• EBITDA grew to Rs 51.9 crore vs Rs 43.8 crore last year. EBITDA Margins also improved to 16.3% vs 15.5% in Q2FY24.
• Profit after Tax improved significantly to Rs 35.0 crore vs Rs 22.9 crore (YoY growth of 52.8%). PAT Margins improved to 11.0% from 8.1%.

H1FY25 Financial Highlights:

• Revenue from Operations grew 18.7% to Rs 612.5 crore vs Rs 516.2 crore during H1FY24.
• EBITDA increased to Rs 96.2 crore vs Rs 76.2 crore (YoY improvement of 26.2%). EBITDA margins improved by 90 bps to 15.7%.
• Profit after Tax grew by 59.2% to Rs 64.5 crore vs Rs 40.5 crore in H1FY24. PAT Margin increased to 10.5% from 7.8%.

Vinay Lohariwala, Managing Director, Innova Captab, said: “As we reflect on our Q2 and first half results for FY25, we are proud to report that our strategic initiatives are yielding tangible growth across all business areas, with a significant improvement in overall profitability.

In Q2 FY25, we achieved YoY revenue growth of 12.5%, while H1FY25 saw an impressive increase of 18.7%. Our PAT demonstrated remarkable growth, with YoY growth of almost 53% in Q2 FY25 and 59% in H1FY25.

We are particularly excited about the progress at our greenfield plant in Jammu, where we recently received ‘Drug Manufacturing License’ from Government of Jammu and Kashmir, Department of Health and Medical Education, Drug Control Organization, Jammu. With other necessary approvals in place, we had already begun manufacturing validation/ trial batches, and now with the receipt of the license, we expect commercialization of the facility within Q3FY25.

Additionally, we are establishing a new R&D facility in Panchkula, Haryana, which will further enhance our innovation capabilities.

Over the past few years, we have consistently demonstrated a high growth trajectory. With these initiatives and by leveraging our existing strengths, we are confident to continue to build growth momentum. We would like to thank our dedicated team and valued stakeholders for their ongoing support as we strive to create a sustainable and prosperous future for our company.”

Result PDF

Pharmaceuticals company Innova Captab announced Q1FY25 results: 

• Revenue from operation is Rs 294.3 crore in Q1FY25 as against Rs 233.2 crore of Q1FY24 registering a growth of 26%.
• The Company’s EBITDA stood at Rs 44.3 crore in Q1FY25 against Rs 32.4 crore of Q1FY24 registering a growth of 37%.
• Profit After Tax (PAT) stood at Rs 29.5 crore in Q1FY25 against Rs 17.6 crore of Q1FY24 registering a growth of 68%

Commenting on the results, Vinay Lohariwala, Managing Director, - Innova Captab said, For Q1FY25, we reported a total income of Rs 296 crores, a 27% growth compared to same quarter previous year. All business areas are experiencing healthy growth and are expected to maintain this momentum in the coming quarters.

Over the past 3-4 years, our revenue has grown at a robust growth rate. With the new Jammu facility, we are optimistic about sustaining this growth trajectory over the next few years.

As a company, we remain committed to driving sustainable growth by exploring new opportunities and focusing on value-added products. The Indian pharmaceutical sector is poised for significant growth in the mid to long term, with both domestic and global MNCs are increasingly seeking reliable and sustainable suppliers like us.

The foundation of Innova is their in-house research and development which helps to focus on building complex product portfolio. As a major CDMO player, Innova caters to India’s top 14 out of 15 pharmaceuticals companies and have license to manufacture products through four state of the art manufacturing facilities at Baddi - Himachal Pradesh, Dehradun - Uttarakhand and at Taloja - Maharashtra while maintaining WHO-GMP, EU-GMP, UK-MHRA and other major registrations with these facilities.

By Q2FY25, the upcoming greenfield plant in Jammu is expected to be commercialized. This facility will have four production blocks: cephalosporin, penicillin, penum and BFS and will manufacture oral solid dosages, dry powder injections, dry syrup, BFS, Large Volume Parenterals and respiratory respule products.

Result PDF

Pharmaceuticals company Innova Captab announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

• Revenue from operation is Rs 262.63 crore in Q4FY24 as against Rs 240.95 crore of previous year registering a growth of 9.0%.
• The Company’s EBITDA stood at Rs 43.76 crore in Q4FY24 against Rs 29.42 crore of previous year registering a growth of 48.7%.
• Profit After Tax (PAT) stood at Rs 28.72 crore in Q4FY24 against Rs 17.25 crore of previous year registering a growth of 66.5%.

FY24 Financial Highlights:

• Total Income for the FY24 stood at Rs 1,093.79 crore against Rs 935.58 crore in FY23 with growth of 16.9% over FY23.
• Revenue from Operation has increased to Rs 1,081.31 crore in FY24 from Rs 926.38 crore in FY23, registering a growth of 16.7%.
• The Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) stands at Rs 166.94 crore in FY24, as against Rs 122.85 crore in FY23, with an increase of 35.9%.
• Profit After Tax (PAT) is Rs 94.35 crore in FY24 as against Rs 67.95 crore in FY23, registering a growth of 38.9%.
• Earnings per share (EPS) for FY24 is Rs 18.66, against Rs 14.16 in FY23
• For FY24, net cash generated from operating activities stood at Rs 146 crore, against Rs 67 crore in FY23.

Commenting on the results, Vinay Lohariwala, Managing Director, - Innova Captab Limited said, For FY24, we reported a total income of Rs 1,094 crore with a growth of 16.9% compared to the previous year. Our all business areas are getting good traction and are expected to grow at a healthy rate in the coming years.

Over the last 3-4 years, we have grown at a healthy rate of ~ 20% CAGR. With our upcoming Jammu facility and recent Sharon acquisition, we are positively looking forward to maintaining the same healthy growth rate over the next 3-4 years.

As a company we continue to drive sustainable growth by exploring new opportunities and focusing on value-added products. Indian pharmaceutical companies are set to experience significant growth in the mid to long term, as both domestic and global manufacturers seek reliable and sustainable suppliers like us.

Result PDF